Insulet Co. (NASDAQ:PODD) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Insulet Co. (NASDAQ:PODD) have received a consensus rating of “Moderate Buy” from the fifteen ratings firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $277.13.

Several research firms have commented on PODD. Citigroup upped their price objective on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. BTIG Research increased their price target on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Canaccord Genuity Group lifted their price objective on shares of Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a report on Monday, December 9th. Barclays upped their price objective on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. Finally, TD Cowen raised their target price on Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, January 3rd.

Insider Buying and Selling at Insulet

In related news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Institutional Trading of Insulet

Several large investors have recently bought and sold shares of the business. Baillie Gifford & Co. boosted its holdings in shares of Insulet by 3.5% during the 4th quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier’s stock worth $614,998,000 after purchasing an additional 79,982 shares during the last quarter. Geode Capital Management LLC boosted its stake in Insulet by 2.3% during the fourth quarter. Geode Capital Management LLC now owns 1,779,167 shares of the medical instruments supplier’s stock worth $463,347,000 after buying an additional 40,566 shares during the last quarter. Norges Bank purchased a new stake in Insulet in the 4th quarter valued at $248,806,000. Artisan Partners Limited Partnership increased its stake in shares of Insulet by 24.1% in the 4th quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier’s stock worth $201,073,000 after acquiring an additional 149,524 shares during the last quarter. Finally, Westfield Capital Management Co. LP raised its holdings in shares of Insulet by 27.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after acquiring an additional 163,388 shares during the period.

Insulet Stock Up 0.9 %

Shares of PODD opened at $282.12 on Friday. The company has a market capitalization of $19.79 billion, a price-to-earnings ratio of 48.31, a PEG ratio of 3.61 and a beta of 1.23. Insulet has a 52 week low of $160.19 and a 52 week high of $289.46. The stock’s 50-day moving average price is $271.44 and its 200-day moving average price is $243.41. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.